Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV †
1
Department of Infectious Diseases, Faculty of General Medicine, Carol Davila University for Medicine and Pharmacy, 020021 Bucharest, Romania
2
“Victor Babes” Clinical Hospital for Infectious and Tropical Diseases, 030303 Bucharest, Romania
3
Royal Free Hospital, London NW3 2QG, UK
*
Author to whom correspondence should be addressed.
†
The article is a revised and expanded version of a paper entitled: “Salvage ART regimen based on a combination of an integrase inhibitor and Doravirine in heavily antiretroviral treated people living with HIV”, which was presented at “HIV Drug Therapy Glasgow Conference”, Glasgow, UK, 10–13 November 2024.
‡
These authors contributed equally to this work.
Microorganisms 2026, 14(2), 390; https://doi.org/10.3390/microorganisms14020390
Submission received: 12 January 2026
/
Revised: 2 February 2026
/
Accepted: 4 February 2026
/
Published: 6 February 2026
(This article belongs to the Special Issue HIV Infections: Comorbidities, Clinical Challenges, and Antiretroviral Advances)
Abstract
Management of heavily treatment-experienced people living with HIV (HTE-PWH) remains challenging due to long antiretroviral therapy (ART) exposure and limited treatment options. We conducted an observational, real-world-data study on HTE-PWH in active care at the “Victor Babeș” Hospital, Bucharest, receiving doravirine (DOR)-based salvage regimens combined with dolutegravir (DTG) or bictegravir (BIC). Epidemiological, clinical, and laboratory variables were analyzed according to HIV acquisition mode and salvage regimen. Sixty-nine PWH were included; 57.9% male, with a median age of 36 years. Median ART duration before switch was 21.5 years. HIV was acquired parenterally in childhood (PM) in 64.7% cases. Salvage regimens included BIC/FTC/TAF + DOR (50.0%), 3TC/TDF/DOR + DTG (35.2%), and 3TC/DTG + DOR (14.7%). The median nadir CD4 count was 37 cells/µL, and the median viral load at diagnosis was 5.24 log10 copies/mL. Switching was performed for regimen simplification (n = 32) or non-adherence-related virological failure (n = 37). At switch, 53.6% had detectable viremia. Viral suppression was achieved in 68.3% at 6 months and 75.0% at 12 months. Individuals with PM infection were younger and had longer ART exposure than those with heterosexual acquisition. DOR-based salvage regimens combined with DTG or BIC were effective in adherent HTE-PWH, particularly those with extensive ART histories.
1. Introduction
The natural history of HIV was significantly influenced by the availability of efficient antiretroviral treatment (ART) with viral suppression, immune reconstitution and improvement of the quality and duration of life [1]. Persons living with HIV (PWH) nowadays have access to novel and efficient antiretroviral treatments (ART) based on high-genetic-barrier drugs, with fewer drug–drug interactions and adverse reactions. Treatment for newly diagnosed individuals is now much less of a challenge, with novel formulations and two-drug and single-tablet regimens [2,3]. However, over time, PWH may experience drug–drug interactions due to polypharmacy and aging, as well as adverse reactions and toxicities, or develop resistance-associated mutations, reducing their therapeutic options. This may result in poor clinical outcomes with increased mortality rates, as well as potentially increasing HIV transmission [2,4].
Heavily treatment-experienced (HTE) is a term currently used for PWH who only have a maximum of two available fully active ARV classes. The prevalence of HTE-PWH varies between geographical regions, impacted by access to integrase inhibitor (INSTI)-based regimens. Achieving and maintaining viral suppression for HTE-PWH is vital, as it improves immune function and reduces clinical disease [1,5,6].
In Romania between the late 1980s and the early 1990s, more than 13,000 children, the ‘HIV pediatric cohort‘, were parenterally infected due to unsafe medical practices in state-run hospitals and orphanages with HIV F1 clade, linked phylogenetically to the Angolan F subtype [7,8]. A significant number of children in hospitals and orphanages were infected, of whom half survived, and in 2025, more than five thousand are still alive. These children who grew up with HIV used all classes of antiretroviral drugs, and due to toxicity, high pill burden, and long treatment duration, many experienced “treatment fatigue” or poor adherence to treatment. The survivors of this pediatric cohort are now young HTE adults living with HIV. However, in the last decade, HIV in Romania has been acquired through sexual contact, both heterosexual (HSX) and same-sex contact (MSM), as well as by injecting drug use (PWIDs). PWIDs living with HIV often have associated neuro-psychiatric disorders and interactions between ART and co-medications or the illegal drugs they use, and many now have similar rates of HTE as those of the pediatric cohort [9,10,11].
The aim of our study was to assess epidemiological aspects and outcomes in PWH under salvage ART regimens based on a combination of a non-nucleoside reverse transcriptase inhibitor—NNRTI (DOR)—and an integrase inhibitor—dolutegravir (DTG) or bictegravir (BIC)—in Romania, as few data on this subject have been published.
2. Materials and Methods
2.1. Patient Population
We conducted an observational, real-world-data study on PWH in active care between 1 January and 31 December 2023 at “Victor Babes” HIV Regional Center, Bucharest, Romania, with a prescribed regimen containing doravirine with either dolutegravir or bictegravir.
Variables of interest were related to socio-demographic and clinical characteristics (age, gender, ART history, comorbidities, reasons for switch), immuno-virological status (CD4 cell count, nadir CD4, plasma viral load at baseline and 6 and 12 months after the switch, respectively) and outcomes. The baseline HIV-RNA value was deemed the last evaluation before the switch. Reasons for switching to a salvage regimen included virologic failure, toxicities, or simplification of a complex ART regimen. These variables were collated from the electronic database and were compared based on HIV mode of acquisition—parenteral mode of HIV acquisition during childhood (PM) and non-PM (HSX, MSM and PWIDs) or salvage ARV regimen (BIC/FTC/TAF + DOR, 3TC/TDF/DOR + DTG and 3TC/DTG + DOR).
2.2. Laboratory Methods
HIV-1 viral loads were measured on Cobas® 6800 instrument (Roche, Basel, Switzerland), with Cobas® HIV-1 test, from Roche, Basel, Switzerland.
CD4 counts were measured using the BD FACS CANTO II flow-cytometer, with BD Multitest™ BD Multitest™ CD3 FITC/CD8 PE/CD45 PerCP/CD4 APC reagent, from Becton Dickinson Biosciences, San Jose, CA, USA.
RNA-HIV not detected (ND) was defined as a viral load (VL) < 40 copies/mL.
However, we reported a threshold of 50 copies/mL because this cut-off is commonly used in data presentation, ensuring consistency and comparability with published literature.
2.3. Statistical Analysis
Statistical comparisons were performed using SPSS vs 20.1. We summarized socio-demographic, clinical and immuno-virological characteristics using interquartile range (IQR) or absolute count (n) and percentage (%) as appropriate. Quantitative variables (CD4 cell count, HIV-RNA value, age, duration on ART) were compared using Mann–Whitney test and qualitative ones (gender, modes of HIV acquisition) using Chi-square test. Statistically significant difference was considered in cases of p-values of less than 0.05.
3. Results
3.1. Socio-Demographic and Clinical Characteristics of PWH on Salvage ART Regimen
During the twelve months of the study, a total of 2710 PWH were in active care, out of which sixty-nine were heavily exposed to ART and were switched or changed to ART salvage regimens. More than half of them, 40 (57.9%), were males, with a median age of 36 years (IQR 35–49). Modes of HIV acquisition were parenteral mode during childhood (PM) 44 (64.7%), heterosexual contact (HSX) 18 (6.4%), injecting drug use (PWID) 3 (4.3%), men having sex with men (MSM) 1 (1.4%) and vertical transmission 3 (4.3%) (Table 1).
Forty-eight (70.5%) PWH had at least one comorbidity, with dyslipidemia (28), neuro-psychiatric (12), cardiovascular (10), diabetes (6) and neoplasia (5) being the most frequent.
ART was switched to a salvage regimen after a median time of 21.5 years (IQR 15.75–24). The median number of previous ART regimens was seven (IQR 5–8.25), with a median time of 15 (IQR 8–20) years under protease inhibitors (PIs), 6 (IQR 3–10) under INSTI and 4 (IQR 2–10) under non-nucleoside reverse transcriptase inhibitors (NNRTIs). The median nadir CD4/µL and CD4/μL at change were 37 (IQR 15–124) and 296 (IQR 151–640), respectively, and the median HIV viral load (log10copies/mL) at HIV diagnosis was 5.24 (IQR 4.71–5.69). Only 31 (45.5%) PWH were undetectable at switch (Table 2).
3.2. Salvage ART Regimens
The reasons for switching were virological failure in 37 (53.6%) and simplification in 32 (46.3%) subjects. ART salvage regimens used were BIC/FTC/TAF + DOR (35, 50.7%), 3TC/TDF/DOR + DTG (24, 35.2%) and 3TC/DTG + DOR (10, 14.7%). Immunological, virological and ART history characteristics were similar irrespective of ART salvage regimen, with no statistically significant differences (Table 3). However, 3TC/DTG + DOR had a higher CD4 cell count (p = 0.049), being used more frequently in PWH adherent to treatment but with toxicities to nucleoside reverse transcriptase inhibitors (NRTIs).
We also compared socio-demographic and clinical characteristics based on HIV mode of acquisition. Compared to individuals with a heterosexual mode of HIV acquisition, those infected parenterally during childhood were younger (p = 0.01) and had a longer duration on ART. However, when we compared PM with all other groups (non-PM), there was no statistically significant difference related to age, but the median duration on ART (all classes) before the initiation of the salvage regimen was still higher in the PM group (Table 4).
3.3. Virological Suppression Rates Under Salvage ARV Regimens
We evaluated the viral suppression rate after the switch to salvage regimens in patients with undetectable HIV VL at baseline. After 6 months, we registered a significant increase in the number of individuals with undetectable HIV viral load (67.7%), and 81.3% had a viral load below 200 copies/mL. These rates were even higher 12 months after the switch, when 76.5% of subjects with available viremia were undetectable, and almost 90% had VL < 200 copies/mL (Figure 1).
We also followed up with the 36 patients with detectable viral loads at baseline. After 6 months the HIV viral load was available for nineteen people, out of which eight (42.1%) were undetectable and 13 (68.4%) had a VL below 200 copies/mL. Similarly, the rates of viral suppression increased at 12 months after the change, with 60.0% being undetectable and 80.0% with low-level viremia (Figure 2).
4. Discussion
In this study we evaluated the outcomes of doravirine plus second-generation integrase inhibitor-based therapies as salvage regimens in HTE-PWH in active care at a Romanian tertiary healthcare facility, comparing outcomes by mode of acquisition.
As stated, Romania has a unique cohort of PWH infected parenterally during childhood with 5000 long-term survivors, now being young adults between 34 and 36 years of age [8,10,11,12]. These PWH received ART since childhood, when the first antiretrovirals became available in Romania, including monotherapy or dual therapy, with ART that are no longer available, having been withdrawn due to toxicities. However, more than half of PWH from this cohort are still alive due to significant efforts made by healthcare professionals to provide access to treatment. Moreover, during their childhood and as young adults, they experienced a lot of stigma and discrimination, and due to the use of toxic drugs, most of them developed lipodystrophy [10,11,12,13].
During the last decades, HIV acquisition in Romania has mainly been sexual, with both different- and same-sex partners, heterosexual transmission of HIV being nowadays the most prevalent one. A high proportion of persons newly diagnosed with HIV are MSMs, who are often young, educated males adherent to treatment, who rarely need salvage ART regimen. Injecting drug use is still a challenge for HIV control in Romania, but the proportion of newly diagnosed cases among injecting drug users significantly decreased since new psychoactive drugs (“ethnobotanical drugs”) became illegal in 2014 [7,10,11,14,15].
Previous studies have shown that PWH with limited treatment options are often older individuals with low CD4 cell counts and high HIV viral load, with a history of NRTI-based mono or dual therapy [5,16]. These characteristics describe the profile of cases from our cohort, except for their age.
Heavily treatment-experienced PWH have limited ART options, and the initial definition of the number of previously used ART regimens was updated, since the actual standard of care includes ART switches in virologically suppressed PWH for simplification to improved available therapies [1]. The patients enrolled in the study were HTE-PWH, irrespective of definitions, with a median of seven previous ART regimens, and almost half, irrespective of the mode of HIV acquisition, were undetectable at switch, which was chosen for the simplification of complex regimens or to avoid toxicities or drug–drug interactions. In the literature, we found very few reports about HTE-PWH being switched to salvage regimens for ART simplification or to reduce the risk of toxicities.
In this study protease inhibitors had the longest median duration of use, followed by integrase inhibitors and non-nucleoside reverse-transcriptase inhibitors. PI-associated mutations are rare in PWH whose first ARV regimen was based on PIs, being more often identified in HTE-PWH who initiated ART in the pre-ART era with nucleoside-based mono or dual therapies and later with unboosted first-generation PIs. These individuals often possess high-level resistance mutations to multiple PIs, including those with a high genetic barrier [17]. Subjects belonging to the HIV pediatric cohort had a significantly higher treatment duration on all classes of antiretrovirals, especially protease inhibitors. More than half of PWH from our study had taken all classes of antiretrovirals and regimens, including mono and dual therapies, with a high probability of significant resistance, explaining virological failure and the importance of salvage ARV regimens in this cohort.
When INSTIs became available in 2006, the longer duration compared to NNRTIs in our HTE-PWH may be explained by the immediate switch to regimens based on this new class of antiretrovirals in PWH with the failure of previous old regimens. In addition, during the last decade, guidelines recommended INSTI-based regimens as the first-line treatment, so all newly diagnosed PWH initiated treatment with these drugs [1].
Even if young by age, the PWH infected in childhood are old by disease. The chronic inflammation generated by HIV due to microbial translocation and damage-associated molecular patterns, with immune activation and proinflammatory cytokines, leads to premature aging and more comorbidities even in young adults. Unfortunately, ART cannot completely restore the T- and B-cell phenotypes, and many persons living with HIV from childhood have accelerated telomere attrition, as well as exhausted and senescent cells, with high risks of developing comorbidities that are more common in the older general population and require association of multiple medications with risk of drug–drug interactions and toxicities [18]. Dyslipidemia, cardiovascular diseases, diabetes, and neoplasms were the most common comorbidities in our cohort, reflecting long-term use of PIs in our cohort.
PWH treated with PI-based regimens, including newer ones, have an elevated risk of coronary heart disease due to alterations in plasma lipids and insulin levels. As prevention, these PWH require statin-based treatments that also lead to drug–drug interactions and adverse reactions, like myopathy or hepatotoxicity. We also identified a high number of neuro-psychiatric disorders, more often in subjects belonging to the pediatric cohort, including depression, anxiety, panic attacks and intellectual disability. Living with HIV since childhood and facing stigma was a challenge for these people, leading to poor adherence to treatment and even the risk of suicide. In order to prevent these events, psychotherapeutic and pharmacological interventions were required [19,20,21].
Novel agents have recently been approved for use in HTE-PWH (ibalizumab, fostemsavir and lenacapavir), all with novel mechanisms of action. Data available so far suggest that, when administered with efficient background regimens, each of these are able to achieve viral suppression in HTE-PWH [22]. Unfortunately, access to these novel medications is limited to some high-resource settings, and they are currently not available in Romania.
Access to genotyping testing in Romania can be limited, so changes to salvage regimens were, in most cases, made without analyzing the resistance-associated mutation profile. The salvage ART regimens used in our study, based on a combination of a non-nucleoside reverse transcriptase inhibitor, doravirine, and an integrase inhibitor—dolutegravir or bictegravir—were very effective in our cohort, as also suggested by other studies [16].
Our outcomes under salvage ART regimens were favorable, with more than 80% of HTE PWH achieving viral loads <200 copies/mL, with even higher rates after 12 months. PWH who were undetectable at ART change maintained their viral suppression, and more than half of those with virologic failure managed to reach viral suppression under the salvage ART regimen, demonstrating once again the efficacy of these combinations.
There remains uncertainty on the best option to simplify extensive ART regimens in HTE-PWH with good adherence and undetectable plasma HIV-RNA: whether an integrase inhibitor-based single tablet regimen (STR) could be sufficient, or if it would still be safer to use a salvage ART regimen.
The results of the “DoDo” study, which proposed an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir for heavily pre-treated patients, showed that this double combination could be a valuable option for ART optimization in persons multiple experienced to treatment who have undetectable loads at switch [23].
There are few published studies describing the experience with ART switch on off-label dual regimens based on DOR and DTG; the majority suggest efficacy and viral replication control. Switching to this regimen was performed in most cases to avoid drug–drug interactions and toxicities; the conclusion obtained was that performing the switch in the absence of genotyping tests and data about resistance-associated mutations is risky, but our study suggests otherwise and that it and other novel combinations can be a suitable option in resource-limited settings [23,24,25].
Limitations
One limitation was a lack of viral-resistance testing. Genotyping was not measured for all patients due to poor adherence to treatment or due to low-level viremia, which makes genotyping tests difficult. The results of the study were based on data from a single clinical center. Although a high proportion of PWH from the south-eastern region of Romania are seen in our center, more generalizable results would have emerged had we collected data from more areas of the country.
5. Conclusions
The number of PWH who switched to salvage ARV regimens in Romania significantly increased during recent years, especially among subjects belonging to the HIV pediatric cohort, with long durations of ART. The salvage ART regimens containing doravirine and dolutegravir or bictegravir all improved outcomes and increased the rates of undetectable HIV RNA in adherent PWH. More data is required to prove if STRs with high genetic barriers are an efficient and durable option in PWH with extensive treatment history or if double regimens with DTG and DOR could also be effective in this group. Our study showed that these salvage regimens, with high genetic barriers to resistance, were efficient even in the absence of prior resistance testing.
Author Contributions
I.I. and C.O. made equal contributions to the manuscript. Conceptualization, I.I. and C.O.; methodology, C.O.; software, I.I. and C.O.; validation, C.O., I.I. and M.Y.; formal analysis, M.Y.; investigation, I.I., R.R., G.T. and C.O.; resources, I.I., R.R., G.T. and C.O.; data curation, I.I. and C.O.; writing—original draft preparation, I.I. and C.O.; writing—review and editing, I.I., M.Y. and C.O.; visualization, I.I., R.R., G.T. and C.O.; supervision, C.O.; project administration, I.I. and C.O. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethic Committee of Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest (protocol code 1477/19.04.2021 reconfirmed on 28 January 2026).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author. The raw patient data are preserved in the electronic database of Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania, and consist of their files (diagnosis, history, outcome, and all laboratory tests).
Acknowledgments
Publication of this paper was supported by the University of Medicine and Pharmacy Carol Davila, through the institutional program Publish not Perish. During the preparation of this manuscript, the authors used ChatGPT 5.2 for the purposes of reducing the number of words in the abstract and reformulating the title. The authors have reviewed and edited the output and take full responsibility for the content of this publication. The article is a revised and expanded version of a paper [26], which was presented at “HIV Drug Therapy Glasgow Conference”, Glasgow UK 10–13 November 2024. The abstract with the title: “Salvage ART regimen based on a combination of an integrase inhibitor and Doravirine and in heavily antiretroviral treated people living with HIV” was published in Journal of International AIDS Society, vol. 27, suppl. 6, HIV Glasgow 10–13 November 2024 (10.1002/jia2/26370).
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
The following abbreviations are used in this manuscript:
| ART | Antiretroviral treatment |
| PWH | Persons living with HIV |
| THE | Heavily treatment-experienced |
| INSTIs | Integrase inhibitors |
| HIV | Human immunodeficiency virus |
| HSX | Heterosexuals |
| PWIDs | Persons who inject drugs |
| DOR | Doravirine |
| DTG | Dolutegravir |
| BIC | Bictegravir |
| 3TC | Lamivudine |
| FTC | Emtricitabine |
| TDF | Tenofovir disoproxil fumarate |
| TAF | Tenofovir alafenamide fumarate |
| MSM | Men having sex with men |
| ND | Not detectable |
| VL | Viral load |
| PM | Parenteral mode of HIV acquisition during childhood |
| PIs | Protease inhibitors |
| NNRTIs | Non-nucleoside reverse transcriptase inhibitors |
| NRTIs | Nucleoside reverse transcriptase inhibitors |
| STR | Single-tablet regimen |
References
- Brizzi, M.B.; Cable, T.L.; Patel, D.C.; Williams, K.; Adjei, Z.; Fichtenbaum, C.J. Heavily treatment-experienced patients with HIV: Are new mechanisms of action enough? J. Int. Med. Res. 2024, 52, 03000605241301883. [Google Scholar] [CrossRef]
- Cluck, D.B.; Chastain, D.B.; Murray, M.; Durham, S.H.; Chahine, E.B.; Derrick, C.; Dumond, J.B.; Hester, E.K.; Jeter, S.B.; Johnson, M.D.; et al. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An exe. Pharmacotherapy 2024, 44, 354–359. [Google Scholar] [CrossRef] [PubMed]
- Gandhi, R.T.; Landovitz, R.J.; Sax, P.E.; Smith, D.M.; Springer, S.A.; Günthard, H.F.; Thompson, M.A.; Bedimo, R.J.; Benson, C.A.; Buchbinder, S.P.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023, 329, 63–84. [Google Scholar] [CrossRef]
- Grover, D.; Copas, A.; Green, H.; Edwards, S.G.; Dunn, D.T.; Sabin, C.; Phillips, A.; Allen, E.; Pillay, D.; on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC). What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J. Antimicrob. Chemother. 2008, 61, 705–713. [Google Scholar] [CrossRef]
- Hsu, R.K.; Fusco, J.S.; Henegar, C.E.; Vannappagari, V.; Clark, A.; Brunet, L.; Lackey, P.C.; Pierone, G.; Fusco, G.P. Heavily treatment-experienced people living with HIV in the OPERA® cohort: Population characteristics and clinical outcomes. BMC Infect. Dis. 2023, 23, 91. [Google Scholar] [CrossRef] [PubMed]
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV; Department of Health and Human Services: Washington, DC, USA, 2024; pp. 1–334. Available online: https://clinicalinfo.hiv.gov/ (accessed on 15 October 2025).
- Oprea, C.; Ianache, I.; Vasile, S.; Costescu, C.; Tardei, G.; Nica, M.; Umlauf, A.; Achim, C. Brain opportunistic infections and tumors in people living with HIV—Still a challenge in efficient antiretroviral therapy era. J. NeuroVirology 2023, 29, 297–307. [Google Scholar] [CrossRef]
- Apetrei, C.; Necula, A.; Holm-Hansen, C.; Loussert-Ajaka, I.; Pandrea, I.; Cozmei, C.; Streinu-Cercel, A.; Pascu, F.-R.; Negut, E.; Molnar, G.; et al. HIV-1 diversity in Romania. Aids 1998, 12, 1079–1085. [Google Scholar] [CrossRef]
- Case Study-Romania—Ceausescu’s Children. 2024. Available online: https://www.hivoutcomes.eu/good-practices/ceausescus-children (accessed on 15 October 2025).
- CNLAS. HIV/AIDS in Romania-update 30th June 2023. 2024. Available online: https://www.cnlas.ro/images/doc/2023/PREZENTARE-30%20iunie-2023-site%20-07.08.2023.pdf (accessed on 15 October 2025).
- CNLAS. HIV History in Romania 30th June 2025. 2025. Available online: https://www.cnlas.ro/index.php/date-statistice (accessed on 15 October 2025).
- Andrioni, F. Trends of HIV/AIDS Phenomenon Dynamics in Romania from. Iran. J. Public Health 2019, 48, 1903–1909. [Google Scholar]
- Apetrei, C.; Descamps, D.; Collin, G.; Robertson, D.L.; Pandrea, I.; Groza, P.; Prisecariu, L.; Teodorescu, I.; Luca, V.; Brun-Vézinet, F. HIV Type 1 Diversity in Northeastern Romania in 2000–2001 Based on Phylogenetic Analysis of pol Sequences from Patients Failing Antiretroviral Therapy. AIDS Res. Hum. Retroviruses 2003, 19, 1155–1161. [Google Scholar] [CrossRef] [PubMed]
- Ianache, I.; Skrzat-Klapaczynska, A.; Jilich, D.; Fleischhans, L.; Gmizic, I.; Ranin, J.; Papadopoulos, A.; Protopapas, K.; Mulabdic, V.; Lakatos, B.; et al. Mpox across countries from Central and Eastern Europe-2022 outbreak. Travel Med. Infect. Dis. 2024, 59, 102719. [Google Scholar] [CrossRef]
- Mărdărescu, M.; Popa, M.-I.; Streinu-Cercel, A. Hiv/Aids in Romania—A Short History and Update, 2021. Rom. Arch. Microbiol. Immunol. 2021, 80, 305–311. [Google Scholar] [CrossRef]
- Bajema, K.L.; Nance, R.M.; Delaney, J.A.; Eaton, E.; Davy-Mendez, T.; Karris, M.Y.; Moore, R.D.; Eron, J.J.; Rodriguez, B.; Mayer, K.H.; et al. Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. AIDS 2020, 34, 2051–2059. [Google Scholar] [CrossRef]
- Tang, M.W.; Shafer, R.W. HIV-1 antiretroviral resistance: Scientific principles and clinical applications. Drugs 2012, 72, e1–e25. [Google Scholar] [CrossRef]
- Dalzini, A.; Petrara, M.R.; Ballin, G.; Zanchetta, M.; Giaquinto, C.; De Rossi, A. Biological Aging and Immune Senescence in Children with Perinatally Acquired HIV. J. Immunol. Res. 2020, 2020, 8041616. [Google Scholar] [CrossRef]
- Clotet, B.; Negredo, E. HIV protease inhibitors and dyslipidemia. AIDS Rev. 2003, 5, 19–24. [Google Scholar] [PubMed]
- Gazzaniga, G.; Ridolfi, M.; Lazzaro, A.; Brogi, T.; Pignatelli, P.; Pastori, D.; Mezzaroma, I. Dyslipidemia and statin use in people with HIV-1 infection: Beyond the lipid-lowering effect. Nutr. Metab. Cardiovasc. Dis. 2025, 35, 104110. [Google Scholar] [CrossRef]
- Medeiros, G.C.; Smith, F.A.; Trivedi, M.H.; Beach, S.R. Depressive Disorders in HIV/AIDS: A Clinically Focused Narrative Review. Harv. Rev. Psychiatry 2020, 28, 146–158. [Google Scholar] [CrossRef] [PubMed]
- Beran, C.; Duggan, J.M.; Sahloff, E.G. A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. J. Pharm. Technol. 2024, 40, 194–201. [Google Scholar] [CrossRef] [PubMed]
- Sammet, S.; Touzeau-Römer, V.; Wolf, E.; Schenk-Westkamp, P.; Romano, B.; Gersbacher, E.; Kastenbauer, U.; Boesecke, C.; Rockstroh, J.; Scholten, S.; et al. The DoDo experience: An alternative antiretroviral 2-drug regimen of doravirine and dolutegravir. Infection 2023, 51, 1823–1829. [Google Scholar] [CrossRef]
- Mazzitelli, M.; Sasset, L.; Leoni, D.; Putaggio, C.; Cattelan, A.M. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy A retrospective analysis. Medicine 2021, 100, e28488. [Google Scholar]
- Denyer, R.; Zemskova, J.; A Benator, D. HIV treatment with dolutegravir and doravirine: Rationale for selection and clinical outcomes in a highly treatment experienced population. Int. J. STD AIDS 2022, 33, 1073–1077. [Google Scholar] [CrossRef] [PubMed]
- Irina, I.; Cristiana, C.; Miruna, D.; Gratiela, T.; Roxana, R.; Cristiana, O. Salvage ART regimen based on a combination of an integrase inhibitor and Doravirine in heavily antiretroviral treated people living with HIV. In Proceedings of the HIV Drug Therapy Glasgow Conference, Glasgow, UK, 10–13 November 2024. [Google Scholar]
Figure 1.
Evaluation of HIV-RNA in plasma after switching to salvage ART regimen.
Figure 2.
Changes in plasma HIV RNA after initiation of salvage ART regimens in PWH with detectable VL at baseline.
Figure 2.
Changes in plasma HIV RNA after initiation of salvage ART regimens in PWH with detectable VL at baseline.
Table 1.
Socio-demographic characteristics of PWH on salvage ARV regimens.
| Characteristics | Total n = 69 | |
|---|---|---|
| Male sex | n (%) | 40 (57.9) |
| Age (years) | median (IQR) | 36 (35–49) |
| Mode of HIV acquisition | ||
| parenteral mode during childhood (PM) | median (IQR) | 44 (64.7) |
| heterosexual contact (HSX) | 18 (26.4) | |
| injecting drug use (PWID) | 3 (4.3) | |
| men having sex with men (MSM) | 1 (1.4) | |
| vertical transmission | 3 (4.3) |
Legend: PM = parenteral mode of HIV acquisition during childhood; HSX = heterosexual contact; PWID = people who inject drugs; MSM = men who have sex with men.
Table 2.
ART history and immuno-virological aspects in PWH on salvage ART regimens.
| Characteristics | Total n = 69 | |
|---|---|---|
| Duration on ART before change (years) | median (IQR) | 21.5 (15.75–24) |
| Nadir CD4 cell count/μL | median (IQR) | 37 (15–124) |
| HIV-RNA (log10copies/mL) at diagnosis | median (IQR) | 5.24 (4.71–5.69) |
| CD4 cell count/μL at change | median (IQR) | 296 (151–640) |
| HIV-RNA at change—ND | n (%) | 31 (45.5) |
| No. of previous ART regimens | median (IQR) | 7 (5–8.25) |
| Duration under INSTI (years) | median (IQR) | 6 (3–10) |
| Duration under PIs (years) | median (IQR) | 15 (8–20) |
| Duration under NNRTIs (years) | median (IQR) | 4 (2–10) |
Legend: ART = antiretroviral treatment; ND = not detected; INSTIs = integrase inhibitors; PIs = protease inhibitors; NNRTIs = non-nucleoside reverse transcriptase inhibitors.
Table 3.
Characteristics of PWH on salvage ART regimens—comparison based on ART regimen.
| Characteristics | BIC/FTC/TAF + DOR N = 35 | 3TC/TDF/DOR + DTG N = 24 | 3TC/DTG + DOR N = 10 | p Value | |
|---|---|---|---|---|---|
| Nadir CD4 cell count/μL | median (IQR) | 75 (21–135) | 44.5 (10–115.5) | 73.5 (22.7–115.5) | 0.610 |
| HIV-RNA at diagnosis log10copies/mL | median (IQR) | 5.08 (4.08–5.69) | 5.16 (4.81–5.44) | 5.76 (5.45–5.96) | 0.187 |
| CD4 cell count at change/μL | median (IQR) | 305 (163–637) | 220 (101–452.5) | 755 (381.5–1035.5) | 0.049 |
| HIV-RNA at change—ND | n (%) | 16 (47.0) | 8 (33.3) | 7 (70.0) | 0.143 |
| Prior ART regimens | n (%) | 7 (5–8.75) | 7 (4.5–8) | 5.5 (5–8.5) | 0.874 |
| Duration under INSTI (years) | median (IQR) | 4 (2–10) | 6 (4.25–7.75) | 8 (5–14) | 0.096 |
| Duration of PIs (years) | median (IQR) | 16.5 (10–21.25) | 13.5 (7.75–17.75) | 12 (5.5–17.5) | 0.339 |
| Duration of NNRTIs (years) | median (IQR) | 4 (2–10.5) | 3 (1–9) | 6.5 (3–11) | 0.529 |
Legend: ND = not detected; INSTIs = integrase inhibitors; PIs = protease inhibitors; NNRTIs = non-nucleoside reverse transcriptase inhibitors.
Table 4.
Characteristics of PWH on salvage ART regimens—comparison based on modes of HIV acquisition.
Table 4.
Characteristics of PWH on salvage ART regimens—comparison based on modes of HIV acquisition.
| Characteristics | PM N = 44 | Non-PM N = 25 | p Value | |
|---|---|---|---|---|
| Male sex | n (%) | 24 (54.5) | 15 (60.0) | 0.612 |
| Age (years) | median (IQR) | 35.5 (35–36) | 44 (34–54.2) | 0.125 |
| Duration of ART before change | median (IQR) | 23.5 (21–25) | 11 (6.75–16.5) | <0.0001 |
| Nadir CD4 cell count/μL | median (IQR) | 80 (12.5–113) | 49.5 (16.7–144.5) | 0.814 |
| HIV-RNA (log10copies/mL) at diagnosis | median (IQR) | 5.23 (4.90–5.69) | 5.26 (4.55–5.69) | 0.957 |
| CD4 cell count at ART change/μL | median (IQR) | 309.5 (175–684.25) | 230.5 (86.25–509.5) | 0.142 |
| HIV-RNA at change—ND | n (%) | 21 (47.7) | 9 (36.0) | 0.472 |
| Prior ART regimens | n (%) | 7 (5.75–9) | 5 (4–6) | <0.0001 |
| Duration on INSTI (years) | median (IQR) | 7 (4–12) | 5 (3.5–6) | <0.0001 |
| Duration of PIs (years) | median (IQR) | 17 (10–21.5) | 4 (2.5–6) | 0.009 |
| Duration on NNRTIs (years) | median (IQR) | 6 (3–10) | 6 (2.75–15) | <0.0001 |
Legend: ND = not detected; INSTIs = integrase inhibitors; PIs = protease inhibitors; NNRTIs = non-nucleoside reverse transcriptase inhibitors.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
MDPI and ACS Style
Ianache, I.; Radoi, R.; Tardei, G.; Youle, M.; Oprea, C. Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV. Microorganisms 2026, 14, 390. https://doi.org/10.3390/microorganisms14020390
AMA Style
Ianache I, Radoi R, Tardei G, Youle M, Oprea C. Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV. Microorganisms. 2026; 14(2):390. https://doi.org/10.3390/microorganisms14020390
Chicago/Turabian StyleIanache, Irina, Roxana Radoi, Gratiela Tardei, Mike Youle, and Cristiana Oprea. 2026. "Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV" Microorganisms 14, no. 2: 390. https://doi.org/10.3390/microorganisms14020390
APA StyleIanache, I., Radoi, R., Tardei, G., Youle, M., & Oprea, C. (2026). Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV. Microorganisms, 14(2), 390. https://doi.org/10.3390/microorganisms14020390
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
